z-logo
Premium
Body weight management and safety with efpeglenatide in adults without diabetes: A phase II randomized study
Author(s) -
Pratley Richard E.,
Kang Jahoon,
Trautmann Michael E.,
Hompesch Marcus,
Han OakPil,
Stewart John,
Sorli Christopher H.,
Jacob Stephan,
Yoon KunHo
Publication year - 2019
Publication title -
diabetes, obesity and metabolism
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.445
H-Index - 128
eISSN - 1463-1326
pISSN - 1462-8902
DOI - 10.1111/dom.13824
Subject(s) - placebo , medicine , body mass index , weight loss , diabetes mellitus , adverse effect , type 2 diabetes , randomized controlled trial , tolerability , obesity , clinical endpoint , endocrinology , gastroenterology , alternative medicine , pathology
Aim To evaluate the safety of efpeglenatide, a long‐acting glucagon‐like peptide‐1 receptor agonist (GLP‐1RA), and its effects on body weight management in adults without diabetes. Materials and methods In this phase II, randomized, placebo‐controlled, double‐blind trial, participants with a body mass index (BMI) ≥30 kg/m 2 or ≥27 kg/m 2 with comorbidity were randomized 1:1:1:1:1 to efpeglenatide (4 mg once weekly, 6 mg once weekly, 6 mg once every 2 wk, or 8 mg once every 2 wk; n = 237) or placebo (n = 60) in combination with a hypocaloric diet. The primary endpoint was body weight change from baseline after 20 wk of treatment, assessed using a mixed‐effect model with repeated measures with an unstructured covariance matrix over all post‐screening visits; treatment comparisons were based on least squares mean estimates. Results Over 20 wk, all doses of efpeglenatide significantly reduced body weight from baseline versus placebo ( P < 0.0001), with placebo‐adjusted reductions ranging between −6.3 kg (6 mg once every 2 wk) and −7.2 kg (6 mg once weekly). Greater proportions of efpeglenatide‐treated participants had body weight loss of ≥5% or ≥10% versus placebo ( P < 0.01, all comparisons). Efpeglenatide led to significant improvements in glycaemic variables (fasting plasma glucose and glycated haemoglobin) and lipid profiles (cholesterol, triglycerides) versus placebo. Rates of study discontinuations as a result of adverse events ranged from 5% to 19% with efpeglenatide. Gastrointestinal effects were the most common treatment‐emergent adverse events. Conclusions Efpeglenatide once weekly and once every 2 wk led to significant body weight reduction and improved glycaemic and lipid variables versus placebo. It was also well tolerated for weight management in adults without diabetes.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here